Related Experiment Video

Updated: Jan 22, 2026

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
06:49

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer

Published on: February 10, 2023

2.7K

A retrospective study of low-dose apatinib combined with S-1 in patients with advanced non-small cell lung cancer

Tong Zhou1, Changling Wu1, Changsong Zhang1

  • 1Department of Medical Oncology, Changzhou Cancer Hospital of Soochow University, Changzhou 213000, China.

Journal of Thoracic Disease
|July 10, 2019
PubMed
Abstract

Insights

Low-dose apatinib combined with S-1 shows promise for advanced non-small cell lung cancer (NSCLC) patients resistant to standard treatments. This combination therapy offers an effective and tolerable option, warranting further investigation in larger trials.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Advanced non-small cell lung cancer (NSCLC) presents treatment challenges with current standard regimens.
  • Limited efficacy of existing therapies necessitates exploration of novel treatment combinations.

Purpose of the Study:

  • To evaluate the efficacy and safety of low-dose apatinib in combination with S-1 therapy.
  • To assess this combination in advanced NSCLC patients who have failed standard treatments.

Main Methods:

  • Retrospective study design involving 31 eligible advanced NSCLC patients.
  • Primary endpoint: Progression-Free Survival (PFS).
  • Secondary endpoints: Overall Response Rate (ORR), Disease Control Rate (DCR), Overall Survival (OS), and safety profile.

Main Results:

  • Median PFS was 102 days; ORR was 22.6%; DCR was 74.2%.
  • Median OS was 422 days.
  • Grade III toxicity observed in 16% of patients; common adverse events included fatigue, hypertension, and hand-foot-skin reaction.

Conclusions:

  • Combination of low-dose apatinib and S-1 is a potentially effective and tolerable treatment for advanced NSCLC patients.
  • Further validation in larger clinical trials is recommended to confirm these findings.
Keywords:
Non-small cell lung cancer (NSCLC)S-1apatinibcombination therapy

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.0K
Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines09:45

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

7.5K

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
229
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
235
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
218
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.2K
Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
281
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
229